Multiple Myeloma: Additional Reading and Resources

Reference	Link
Chari A, Vogul DT, Gavriatopoulou M, et al. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma. *N Engl J Med*. 2019;381:727-738.	https://www.nejm.org/doi/full/10.1056/NEJMoa1903455
Cho SF, Anderson KC, Tai Y-T. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. *Front Immunol*. 2018;9:1821.	https://pubmed.ncbi.nlm.nih.gov/30147690/
D'Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? *Leukemia*. 2020;34:21-34.	https://pubmed.ncbi.nlm.nih.gov/31780814/
D'Souza A, Shah N, Rodriguez C, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. *J Clin Oncol*. 2022;40:3576-3586.	https://pubmed.ncbi.nlm.nih.gov/36029527/
Farooq AV Esposti S, Popat R, et al. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. *Ophthalmol Ther*. 2020;9:889-911.	https://pubmed.ncbi.nlm.nih.gov/32712806/
Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. 2019;33:2266-2275.	https://pubmed.ncbi.nlm.nih.gov/30858549/
Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. *Lancet.* 2020;396:1563-1573.	https://pubmed.ncbi.nlm.nih.gov/33189178/
Guglielmelli T, Palumbo A. Multiple myeloma: is a shift toward continuous therapy needed to move forward? *Expert Rev Hematol.* 2015;8:253-256.	https://pubmed.ncbi.nlm.nih.gov/25582032/
June CH, O'Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. *Science.* 2018;359:1361-1365.	https://pubmed.ncbi.nlm.nih.gov/29567707/
Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. *Leukemia*. 2016;30:1005-1017.	https://pubmed.ncbi.nlm.nih.gov/26710887/
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood.* 2014;124:188-195.	https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management

Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant.* 2019;25:625-638.	https://pubmed.ncbi.nlm.nih.gov/30592986/
Li J, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. *Cancer Cell.* 2017;31:383-395.	https://pubmed.ncbi.nlm.nih.gov/28262555/
Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol*. 2020;21:207-221.	https://www.sciencedirect.com/science/article/abs/pii/S1470204519307880
Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. *Cancer*. 2021;127:4198-4212.	https://pubmed.ncbi.nlm.nih.gov/34314018/
Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. *N Engl J Med*. 2022;387:495-505.	https://pubmed.ncbi.nlm.nih.gov/35661166/
Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncol*. 2021;22:e105-e118.	https://pubmed.ncbi.nlm.nih.gov/33662288/
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nat Rev Clin Oncol*. 2018;15:47-62.	https://pubmed.ncbi.nlm.nih.gov/28925994/
Parikh K, Cang S, Sekhri A, Lui D. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. *J Hematol Oncol*. 2014;7:78.	https://pubmed.ncbi.nlm.nih.gov/25316614/
Perica K, Curran KJ, Brentjens RJ, Giralt SA, et al. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. *Biol Blood Marrow Transplant*. 2018;24:1135-1141.	https://www.sciencedirect.com/science/article/pii/S1083879118301046
Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2022;97(8):1086-1107.	https://pubmed.ncbi.nlm.nih.gov/35560063/
Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. *Blood Cancer J*. 2020;10:94.	https://pubmed.ncbi.nlm.nih.gov/32989217/
Richard S, Richter J, Jagannath S, et al. Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma. *Future Oncol*. 2020;16:1331-1350.	https://pubmed.ncbi.nlm.nih.gov/32511022/
Sanchez L, et al. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. *Ther Adv Hematol.* 2021;12:1-16.	https://journals.sagepub.com/doi/full/10.1177/2040620721989585

Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. *Br J Haematol*. 2012;158:727-738.	https://pubmed.ncbi.nlm.nih.gov/22804669/
Shalabi H, Gust J, Taraseviciute A, et al. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. *Nat Rev Clin Oncol.* 2021;18:363-378.	https://pubmed.ncbi.nlm.nih.gov/33495553/
Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. *Haematologica.* 2016;101:396-406.	https://pubmed.ncbi.nlm.nih.gov/27033237/
Sonneveld P, De Wit E, Moreau P. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. *Crit Rev Oncol Hematol.* 2017;112:153-170.	https://www.sciencedirect.com/science/article/pii/S1040842817300604
Tai Y-T, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. *Leukemia*. 2014;28:155-165.	https://pubmed.ncbi.nlm.nih.gov/23588715/
Tai Y-T, Mayes PA, Acharya C, et al. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. *Blood*. 2014;123:3128-3138.	https://ashpublications.org/blood/article/123/20/3128/32697/Novel-anti-B-cell-maturation-antigen-antibody-drug
Tanenbaum B, Miett T, Patel S. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. *Ann Hematol*. 2023;102(1):1-11.	https://pubmed.ncbi.nlm.nih.gov/36462062/
Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. *Blood Adv.* 2021;5:2196-2215.	https://pubmed.ncbi.nlm.nih.gov/33890981/
Yang J, Zhou W, Li D, et al. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma *Cancer Lett*. 2023;553:215949.	https://pubmed.ncbi.nlm.nih.gov/36216149/
Young RM, Engelet al NW, Uslu, U, Wellhausen N, June CH. Next-Generation CAR T-cell Therapies. *Cancer Discov.* 2022;12:1625-1633.	https://pubmed.ncbi.nlm.nih.gov/35417527/

Resources and Associations	Address
American Cancer Society: Multiple Myeloma	https://www.cancer.org/cancer/multiple-myeloma.html
International Myeloma Foundation	https://www.myeloma.org/
Leukemia and Lymphoma Society: Myeloma	https://www.lls.org/support-resources/other-helpful-organizations/blood-cancer-general-information/myeloma
Multiple Myeloma Research Foundation	https://themmrf.org/
National Comprehensive Cancer Network (NCCN). Multiple myeloma, version 2.2023	www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf